Recently, SATB1 has been found to be overexpressed in several kinds of malignant tumors, such as breast carcinoma [7], gastric carcinoma, laryngeal, hepatocellular, ovarian and bladder carcinoma and in cutaneous malignant melanoma [8]–[14], and evidence suggests SATB1 overexpression is significantly associated with clinicopathologic findings in these neoplasms [3]. Here, SATB1 is linked to urinary bladder carcinoma.